Key Takeaways The two main players in the global obesity market are Eli Lilly (LLY) and Novo Nordisk (NVO) , with their respective GLP-1 injectable therapies, Zepbound and Wegovy, leading the field. Although Zepbound entered the market after Wegovy, it has achieved rapid sales growth, fueled by strong demand. LLY had been enjoying a significant edge over Novo Nordisk, after Zepbound outperformed Wegovy in weight-loss efficacy in a head-to- head clinical study. In the first half of 2025, Zepbound generated $ ...